| Autor: |
Shtam, T. A., Demyanov, A. V., Garaeva, L. A., Emelianova, S. S., Nikitina, A. V., Putevich, E. D., Potyseva, A. S., Bidghieva, M. S., Volnitskiy, A. V., Kvanchiani, V. V., Solomina, L. A., Shabalin, K. A., Sergeeva, E. V., Trashkov, A. P., Sidorova, Zh. Yu., Zhahov, A. V., Burdakov, V. S., Verlov, N. A., Konevega, A. L. |
| Zdroj: |
Nanobiotechnology Reports; April 2024, Vol. 19 Issue: 2 p291-298, 8p |
| Abstrakt: |
Vascular endothelial growth factor receptor-1 (VEGFR-1) plays a critical role in tumor-associated angiogenesis. VEGFR-1 is found on the surface of tumor cells and cells in the tumor microenvironment. Blocking this receptor leads to the suppression of proliferation and increased apoptosis of tumor cells, reduction of tumor vascularization, inhibition of the production of immunosuppressive cytokines by tumor-associated macrophages, and the suppression of tumor invasion and metastasis. The creation of monoclonal antibody drugs that block VEGFR-1 is an urgent task in the development of potential antitumor therapeutic drugs. Target molecules created on the basis of antibodies that bind to VEGFR-1 are a promising basis for the creation of theranostic radiopharmaceuticals for the diagnosis and treatment of malignant neoplasms. To study the therapeutic potential of VEGFR-1 inhibition in breast and colon cancers using antibodies, monoclonal antibodies against recombinant human VEGFR-1 protein are developed. The resulting monoclonal antibodies bind to the VEGFR-1 receptor on the cell surface and effectively inhibit the proliferation of breast and colon cancer cells in vitro, reduce the growth rate of the tumor node in vivo, and prolong the survival of tumor-inoculated mice. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink